CN109562138B - 蛋白质界面 - Google Patents

蛋白质界面 Download PDF

Info

Publication number
CN109562138B
CN109562138B CN201780046940.6A CN201780046940A CN109562138B CN 109562138 B CN109562138 B CN 109562138B CN 201780046940 A CN201780046940 A CN 201780046940A CN 109562138 B CN109562138 B CN 109562138B
Authority
CN
China
Prior art keywords
cell
rad51
compound
cells
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780046940.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109562138A (zh
Inventor
查理·沙赫翁
玛丽亚·索罗维奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthex Inc
Original Assignee
Synthex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthex Inc filed Critical Synthex Inc
Priority to CN202310203866.1A priority Critical patent/CN116217657A/zh
Publication of CN109562138A publication Critical patent/CN109562138A/zh
Application granted granted Critical
Publication of CN109562138B publication Critical patent/CN109562138B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
CN201780046940.6A 2016-05-27 2017-05-26 蛋白质界面 Active CN109562138B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310203866.1A CN116217657A (zh) 2016-05-27 2017-05-26 蛋白质界面

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342840P 2016-05-27 2016-05-27
US62/342,840 2016-05-27
US201662384226P 2016-09-07 2016-09-07
US62/384,226 2016-09-07
PCT/US2017/034870 WO2017205852A2 (en) 2016-05-27 2017-05-26 Protein interfaces

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310203866.1A Division CN116217657A (zh) 2016-05-27 2017-05-26 蛋白质界面

Publications (2)

Publication Number Publication Date
CN109562138A CN109562138A (zh) 2019-04-02
CN109562138B true CN109562138B (zh) 2023-03-21

Family

ID=60411842

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780046940.6A Active CN109562138B (zh) 2016-05-27 2017-05-26 蛋白质界面
CN202310203866.1A Pending CN116217657A (zh) 2016-05-27 2017-05-26 蛋白质界面

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310203866.1A Pending CN116217657A (zh) 2016-05-27 2017-05-26 蛋白质界面

Country Status (9)

Country Link
US (4) US10188691B2 (enExample)
EP (2) EP3463414B1 (enExample)
JP (3) JP7080878B2 (enExample)
CN (2) CN109562138B (enExample)
AU (4) AU2017271678B2 (enExample)
BR (1) BR112018074472A2 (enExample)
CA (1) CA3025423A1 (enExample)
MX (2) MX2018014366A (enExample)
WO (1) WO2017205852A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014366A (es) 2016-05-27 2019-04-11 Synthex Inc Interfaces de proteina.
WO2019099678A1 (en) 2017-11-16 2019-05-23 Synthex, Inc. Selective modulation of protein-protein interactions
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
CN114401730A (zh) * 2019-05-01 2022-04-26 因内特生物制品有限责任公司 免疫调节组合物和方法
WO2020232343A1 (en) 2019-05-15 2020-11-19 Synthex, Inc. Selective degradation of proteins
JP2023145812A (ja) * 2020-08-17 2023-10-12 国立大学法人東海国立大学機構 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
WO2000042064A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptide zur inhibierung von hpv e6-proteinen
CN1768142A (zh) * 2003-04-18 2006-05-03 国际遗传工程和生物技术中心 嵌合多肽及其用途
CN1905864A (zh) * 2003-12-01 2007-01-31 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
US5733726A (en) 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)
WO1998007845A1 (en) 1996-08-23 1998-02-26 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
CA2417135C (en) 1997-11-19 2005-04-12 Microbia, Inc. Chimeric pre-activated transcription factors
WO1999025735A1 (en) 1997-11-19 1999-05-27 Microbia, Inc. Chimeric pre-activated transcription factors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
DE69935313T2 (de) 1998-01-09 2007-11-15 Phylogica Ltd., Northbridge Nachweisverfahren für peptide
IL138353A0 (en) 1998-03-26 2001-10-31 Glaxo Group Ltd Assay methods
US6332897B1 (en) 1998-03-27 2001-12-25 Glaxo Wellcome Inc. Assay methods
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6114111A (en) 1998-03-30 2000-09-05 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
WO2000053630A2 (en) 1999-03-09 2000-09-14 Lexicon Genetics Incorporated COMPOUNDS THAT DISRUPT MAMMALIAN Rad51 ACTIVITY
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
DE60043889D1 (en) 1999-06-07 2010-04-08 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
US6790607B1 (en) 1999-10-07 2004-09-14 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
JP2004500805A (ja) 1999-10-07 2004-01-15 ハイブリジェン、インコーポレイテッド 検出および分析のためのタンパク質−タンパク質相互作用系を含む調整可能な感度の遺伝子的分子相互作用系
US20020086840A1 (en) 2000-01-26 2002-07-04 Zarling David A. Use of Rad51 inhibitors for p53 gene therapy
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7105341B2 (en) 2000-03-06 2006-09-12 Rigel Pharmaceuticals. Inc. In vivo production of cyclic peptides
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
AU2001245584B2 (en) 2000-03-08 2007-02-08 Phylogica Limited Improved reverse n-hybrid screening method
US20030211495A1 (en) 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
WO2001066787A1 (en) 2000-03-08 2001-09-13 Tvw Telethon Institute For Child Health Research Improved reverse n-hybrid screening method
GB0006572D0 (en) 2000-03-17 2000-05-10 Isis Innovation Novel transcription transactivator protein
AU2001283226A1 (en) 2001-08-09 2003-02-24 Pangene Corporation Methods and compositions for inhibiting rad51
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
AU2003279461A1 (en) * 2002-11-07 2004-06-07 Imperial College Innovations Limited Disorders of lipid metabolism
JP2004215624A (ja) * 2003-01-17 2004-08-05 Celestar Lexico-Sciences Inc 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
JP2005095613A (ja) 2003-09-04 2005-04-14 Taiyo Parts Kk 昇降装置
JPWO2005095613A1 (ja) 2004-03-30 2008-02-21 ジェノミディア株式会社 Ｒａｄ５１の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
EP1810028A2 (en) 2004-10-14 2007-07-25 Rigel Pharmaceuticals, Inc. Heterocyclic inhibitors of ires-mediated translation and methods of use thereof
JP2010514777A (ja) 2006-12-26 2010-05-06 ファーマサイクリックス，インク． 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
US8759089B2 (en) 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US7892823B2 (en) 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8105493B2 (en) 2007-06-29 2012-01-31 Jnc Corporation Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
US9273100B2 (en) 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
WO2012019157A2 (en) 2010-08-06 2012-02-09 The Regents Of The University Of California Expression and purification of fusion protein with multiple mbp tags
US9249410B2 (en) 2010-12-15 2016-02-02 The Johns Hopkins University Two-hybrid based screen to identify disruptive residues at multiple protein interfaces
US10912761B2 (en) 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
WO2015138377A1 (en) 2014-03-10 2015-09-17 The University Of Chicago Methods of treating cancer using rad51small molecule stimulators
US10421753B2 (en) 2015-03-02 2019-09-24 The Regents Of The University Of California RAD51 inhibitors and uses thereof
MX2018014366A (es) 2016-05-27 2019-04-11 Synthex Inc Interfaces de proteina.
WO2019099678A1 (en) 2017-11-16 2019-05-23 Synthex, Inc. Selective modulation of protein-protein interactions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
WO2000042064A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptide zur inhibierung von hpv e6-proteinen
CN1768142A (zh) * 2003-04-18 2006-05-03 国际遗传工程和生物技术中心 嵌合多肽及其用途
CN1905864A (zh) * 2003-12-01 2007-01-31 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRCA2的BRC4基元与RAD51相互作用位点的研究进展;赵东欣等;《生命科学》;20150228;第27卷(第2期);第198-202页 *
Mechanistic Insights into RAD51-associated Protein 1 (RAD51AP1) Action in Homologous DNA Repair;M. H. Dunlop等;《J Biol Chem》;20120406;第287卷(第15期);第12343-12347页 *
类BRC4肽的合成及与RAD51（231-260）的相互作用;王莹;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20150515(第05期);E072-170 *

Also Published As

Publication number Publication date
EP4269427A2 (en) 2023-11-01
US20210252100A1 (en) 2021-08-19
BR112018074472A2 (pt) 2019-03-19
EP3463414A2 (en) 2019-04-10
AU2017271678A1 (en) 2018-12-13
US20250177474A1 (en) 2025-06-05
EP4269427A3 (en) 2023-11-22
JP2024099695A (ja) 2024-07-25
US20190216879A1 (en) 2019-07-18
JP2022119883A (ja) 2022-08-17
JP7479421B2 (ja) 2024-05-08
MX2023002591A (es) 2024-02-08
EP3463414A4 (en) 2019-10-23
AU2021205010A1 (en) 2021-08-05
CA3025423A1 (en) 2017-11-30
MX2018014366A (es) 2019-04-11
EP3463414B1 (en) 2023-09-13
AU2022259709A1 (en) 2022-11-24
WO2017205852A3 (en) 2018-01-25
JP7080878B2 (ja) 2022-06-06
CN116217657A (zh) 2023-06-06
WO2017205852A2 (en) 2017-11-30
CN109562138A (zh) 2019-04-02
AU2017271678B2 (en) 2021-05-06
US12214008B2 (en) 2025-02-04
EP3463414C0 (en) 2023-09-13
AU2024204362A1 (en) 2024-07-11
US10188691B2 (en) 2019-01-29
US20170368132A1 (en) 2017-12-28
AU2021205010B2 (en) 2022-08-11
JP2019527066A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
JP7479421B2 (ja) タンパク質界面
US20240018188A1 (en) Compounds for selective disruption of protein-protein interactions
Gray et al. Directed evolution of cyclic peptides for inhibition of autophagy
US8119601B2 (en) Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
AU2025205399A1 (en) Compositions for use in lysis of selective cancer cells
US12281180B2 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
HK40007101B (en) Protein interfaces
HK40007101A (en) Protein interfaces
US9145554B2 (en) Cancer therapy method
WO2022238706A1 (en) Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
KR20230110557A (ko) 종양의 치료를 위한 4-아미노-N-[4-(메톡시메틸)페닐]-7-(1-메틸시클로프로필)-6-(3-모르폴리노프로프-1-인-1-일)-7H-피롤로[2,3-d]피리미딘-5-카르복스아미드의 사용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant